MedTrace Logo

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

NCT01543763 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-03-21

No results posted yet for this study

Summary

This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.

Conditions

  • Metastatic Solid Tumors

Interventions

DRUG

PZP115891, PCI-24781

PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19 PZP115891: oral, 400 - 800 mg qd 28 days per cycle

Sponsors & Collaborators

  • Pharmacyclics LLC.

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Xynomic Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease

    collaborator UNKNOWN

  • Pamela Munster

    lead OTHER

Principal Investigators

  • Pamela Munster, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-25
Primary Completion
2024-01-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543763 on ClinicalTrials.gov